DSGN vs. CTNM, PYXS, IMMP, TSVT, NKTR, ENTA, CTMX, XERS, XBIT, and RAPT
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Contineum Therapeutics (CTNM), Pyxis Oncology (PYXS), Immutep (IMMP), 2seventy bio (TSVT), Nektar Therapeutics (NKTR), Enanta Pharmaceuticals (ENTA), CytomX Therapeutics (CTMX), Xeris Biopharma (XERS), XBiotech (XBIT), and RAPT Therapeutics (RAPT). These companies are all part of the "pharmaceutical preparations" industry.
Design Therapeutics (NASDAQ:DSGN) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.
In the previous week, Design Therapeutics had 7 more articles in the media than Contineum Therapeutics. MarketBeat recorded 9 mentions for Design Therapeutics and 2 mentions for Contineum Therapeutics. Design Therapeutics' average media sentiment score of 0.81 beat Contineum Therapeutics' score of 0.53 indicating that Design Therapeutics is being referred to more favorably in the media.
56.6% of Design Therapeutics shares are owned by institutional investors. 25.7% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Design Therapeutics currently has a consensus target price of $6.60, indicating a potential upside of 46.34%. Contineum Therapeutics has a consensus target price of $28.00, indicating a potential upside of 82.89%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Contineum Therapeutics is more favorable than Design Therapeutics.
Design Therapeutics received 7 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 34.48% of users gave Design Therapeutics an outperform vote.
Contineum Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity.
Summary
Contineum Therapeutics beats Design Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
